DEALS: Amgen acquires Abgenix for $2.2 billion

DEALS

WHO

WITH

WHAT

SCOOP

Amgen

Abgenix

$2.2 billion acquisition

The acquisition of Abgenix provides Amgen with full ownership of panitumumab, a colon cancer drug

Pharmion

GPC Biotech

$270 million licensing deal

The deal is for the co-development and license agreement for satraplatin, an oral platinum-based compound

AstraZeneca

Protherics

£195 million licensing deal

AstraZeneca has signed a development and commercialization agreement for Protherics' anti-sepsis treatment CytoFab

MedImmune

Biota Holdings

$112.5 million licensing deal

It is a collaboration to develop small-molecule compounds for preventing respiratory syncytial virus in infants

GlaxoSmithKline

Vertex

$20 million licensing deal

GSK will develop and commercialize VX-409, Vertex's subtype selective sodium channel modulator for the treatment of pain

Avigen

Genzyme Corporation

$12 million licensing deal

The deal is for the development of non-pain related AAV gene therapy assets

Indevus

Savient Pharmaceuticals

$5 million licensing deal

Savient is selling its injectable testosterone product for male hypogonadism, Delatestryl

Cyclacel

Xcyte

Merger agreement

The transaction will create a publicly-traded international biopharmaceutical company called Cyclacel Pharmaceuticals

ActivBiotics

Metaphore Pharmaceuticals

Merger agreement

Metaphore will become a wholly owned subsidiary of ActivBiotics